Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)
Status:
Terminated
Trial end date:
2017-10-16
Target enrollment:
Participant gender:
Summary
The study is designed as a Phase III, multicenter trial comparing outcomes after allogeneic
hematopoietic stem cell transplantation (HCT) for acute myeloid leukemia (AML) or
myelodysplastic syndrome (MDS) between patients receiving myeloablative conditioning (MAC)
versus reduced intensity conditioning (RIC) regimens.
Phase:
Phase 3
Details
Lead Sponsor:
Medical College of Wisconsin
Collaborators:
Blood and Marrow Transplant Clinical Trials Network National Cancer Institute (NCI) National Heart, Lung, and Blood Institute (NHLBI) National Marrow Donor Program